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Clinical Trials
BNP Predicts Risk of Death or CHF, But Not Benefit From ACE-I
Baseline plasma B-type natriuretic peptide (BNP) and (N-terminal) NT-proBNPconcentrations were measured in 3,761 patients with stable coronary artery
disease and preserved left ventricular function participating in the PEACE trial, a
long-term, placebo-controlled trial of trandolapril. Both BNP andNT-proBNP levels
were strongly related to the risk of cardiovascular mortality, heart failure, and stroke,
but not myocardial infarction; both added additional prognostic information to
traditional risk factors.Therewasnobenefit to trandolapril in theoverall trial; therewas
no difference in patients with high or lowbaseline BNP levels. This suggests that BNPs
addprognostic value in low-risk patientswith stable coronary artery disease.Seepage
205. See figure.
Coronary Risk Stratification
Predicting Cardiac Risk in Patients With Kidney Disease
Patients with chronic kidney disease (CKD) are known to have higher rates ofincident coronary disease, but whether this represents a confluence of multiple
cardiac risk factors or is independent remains controversial.Weiner and colleagues used
the Framingham equations to calculate future cardiac risk in patients with glomerular
filtration rate 15 to 60 ml/min/1.73 m2 (mean creatinine 1.5 mg/dl). The 5- and
10-year risk of cardiac events was nearly twice as high as predicted by the Framingham
model and the discriminating ability was substantially reduced. Further analyses
showed that if the risk factors used in themodelwere “re-weighted,” the accuracy of the
model improved suggesting that traditional risk factors are still important, but the
magnitude of importance is altered by the presence of CKD. See page 217.
Heart Rhythm Disorders
Heart Rate Dependence of QT Length Predicts Arrhythmic Risk
Iacoviello and colleagues hypothesized that the QT interval should provide valuableinformation regarding the subsequent risk of arrhythmia in patients with idiopathic
dilated cardiomyopathy (DCM). Subjects underwent standard electrocardiogrameval-
uation and 24- h Holter recordings. The dependence of the QT interval on heart rate
was calculated bymeasuring both theQTandRR intervals every 30 s for 24h and then
plotting a regression line for each subject. Those with the steepest lines had the most
variability in the length of the QT interval. This regression line calculation proved
nearly as robust at stratifying the arrhythmic risk as the ejection fraction. This novel
calculation, which they term QT dynamicity, may improve the accuracy of risk
stratification in patients with DCM. See page 225.
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Cardiac Resynchronization
Therapy
Measuring Dyssynchrony With CMR Provides Powerful Risk Stratification
Chalil and colleagues developed and tested a novel method for measuring intra-ventricular dyssnchrony which they term cardiovascular magnetic resonance
tissue synchronization imaging (CMR-TSI).This technique slices the left ventricle into
8 short-axis layers and then measures radial motion along 100 cords; the time of peak
radial motion can then be assessed for each cord. Over 2 years of follow-up, patients
with a CMR-TSI110 ms were nearly 4 times more likely to suffer a cardiovascular
death than those with a CMR-TSI110ms, despite both groups undergoing cardiac
resynchronization therapy (CRT). The novel measure of myocardial dyssynchrony
appears to be a powerful independent predictor of mortality and morbidity following
CRT. See page 243. See figure.
